← Leaderboards
Robert Walter Buckheit
Southern Research Institute
$12,955,650
Attributed
$13,354,528
Total exposure
16
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6M · FY2005–16$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$34,310,230 · 18
By mechanism
U19$27,505,598 · 6
R44$2,587,844 · 2
R33$1,406,596 · 1
R21$1,204,619 · 4
R43$1,005,602 · 4
N01$599,971 · 1
Top collaborators
- Duane Ruffner2 shared
- Guangshun Wang2 shared
Others in their field
Top investigators on “Microbicide”
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$236,162,238
- Sten H Vermund · University Of Alabama At Birmingham$126,807,672
- Constance Ann Benson · University Of California, San Diego$121,929,528
- Zvavahera Mike Chirenje · University Of California, San Francisco$117,489,864
- Daniel R Kuritzkes · Brigham And Women'S Hospital$110,608,809
- Elizabeth Renata Brown · Fred Hutchinson Cancer Center$66,500,302
Research focus
MicrobicideEvaluationIn VitroTransmission ProcessVaginaBasePharmacologic SubstanceDrug KineticsBiologicalVirusPharmaceutical PreparationsDoseCellsAntiviral AgentsHiv-1Product DevelopmentToxic EffectNonhuman PrimateProgramsPropertyInfectionPreventIn Vitro AssayPharmacodynamics
Grant awards (47)
Development and Evaluation of Dual Compartment Combination Microbicides$2,149,121
U19 · FY2016 · AI · contact PI
Determination of Dosing Concentrations of Formulated APIs using the MTSA$261,983
U19 · FY2016 · AI · contact PI
Administrative$92,242
U19 · FY2016 · AI · contact PI
Critical Path IND-enabling Studies, Regulatory, and Product Development$66,247
U19 · FY2016 · AI · contact PI
Development and Evaluation of Dual Compartment Combination Microbicides$2,443,193
U19 · FY2015 · AI · contact PI
Determination of Dosing Concentrations of Formulated APIs using the MTSA$322,941
U19 · FY2015 · AI · contact PI
Critical Path IND-enabling Studies, Regulatory, and Product Development$135,311
U19 · FY2015 · AI · contact PI
Administrative$114,079
U19 · FY2015 · AI · contact PI
Development and Evaluation of Dual Compartment Combination Microbicides$2,876,353
U19 · FY2014 · AI · contact PI
Critical Path IND-enabling Studies, Regulatory, and Product Development$464,073
U19 · FY2014 · AI · contact PI
Administrative$274,428
U19 · FY2014 · AI · contact PI
Determination of Dosing Concentrations of Formulated APIs using the MTSA$94,269
U19 · FY2014 · AI · contact PI
Development and Evaluation of Dual Compartment Combination Microbicides$3,574,067
U19 · FY2013 · AI · contact PI
Critical Path IND-enabling Studies, Regulatory, and Product Development$939,369
U19 · FY2013 · AI · contact PI
Determination of Dosing Concentrations of Formulated APIs using the MTSA$278,481
U19 · FY2013 · AI · contact PI
Administrative$94,483
U19 · FY2013 · AI · contact PI
Development and Evaluation of Dual Compartment Combination Microbicides$3,224,012
U19 · FY2012 · AI · contact PI
Long Acting Acceptable Microbicides: Novel Delivery, Activity and Pharmacodynamic$1,080,708
U19 · FY2012 · AI · contact PI
Critical Path IND-enabling Studies, Regulatory, and Product Development$942,042
U19 · FY2012 · AI · contact PI
Determination of Dosing Concentrations of Formulated APIs using the MTSA$337,523
U19 · FY2012 · AI · contact PI
Advanced Preclinical and Clinical Development and Regulatory Evaluations$301,809
U19 · FY2012 · AI · contact PI
Administrative$95,368
U19 · FY2012 · AI · contact PI
Long Acting Acceptable Microbicides: Novel Delivery, Activity and Pharmacodynamic$1,265,859
U19 · FY2011 · AI · contact PI
Advanced Preclinical and Clinical Development and Regulatory Evaluations$864,582
U19 · FY2011 · AI · contact PI
Mechanism of Action of Novel Dual Acting Pyrimidinediones$861,701
R44 · FY2011 · AI · contact PI
Development of Antimicrobial Peptides as Topical Microbicides$195,117
R21 · FY2011 · AI · contact PI
Discovery of drugs for use in the treatment and prevention of HIV infection using$133,859
R43 · FY2011 · AT
Long Acting Acceptable Microbicides: Novel Delivery, Activity and Pharmacodynamic$1,578,326
U19 · FY2010 · AI · contact PI
Mechanism of Action of Novel Dual Acting Pyrimidinediones$919,455
R44 · FY2010 · AI · contact PI
Advanced Preclinical and Clinical Development and Regulatory Evaluations$870,666
U19 · FY2010 · AI · contact PI
Rational Development of Combination Microbicide Therapies$426,388
R33 · FY2010 · AI · contact PI
Discovery of drugs for use in the treatment and prevention of HIV infection using$268,332
R43 · FY2010 · AT
Development of a Novel Semen-Activated Prodrug as an Anti-HIV Microbicide$204,587
R21 · FY2010 · AI · contact PI
Development of Antimicrobial Peptides as Topical Microbicides$200,449
R21 · FY2010 · AI · contact PI
Long Acting Acceptable Microbicides: Novel Delivery, Activity and Pharmacodynamic$1,389,746
U19 · FY2009 · AI · contact PI
Rational Development of Combination Microbicide Therapies$435,378
R33 · FY2009 · AI · contact PI
Development of Pyrimidinedione NNRTIs With a High Genetic Barrier to Resistance$231,102
R43 · FY2009 · AI · contact PI
Development of a Novel Semen-Activated Prodrug as an Anti-HIV Microbicide$186,236
R21 · FY2009 · AI · contact PI
Long Acting Acceptable Microbicides: Novel Delivery, Activity and Pharmacodynamic$1,374,317
U19 · FY2008 · AI · contact PI
Rational Development of Combination Microbicide Therapies$544,830
R33 · FY2008 · AI · contact PI
Development of Pyrimidinedione HIV Inhibitors as Topical Microbicides$364,532
R44 · FY2008 · AI · contact PI
Mechanism of Action of Novel Dual Actiing Pyrimidinediones$272,483
R43 · FY2008 · AI · contact PI
Development of Pyrimidinedione HIV Inhibitors as Topical Microbicides$442,156
R44 · FY2007 · AI · contact PI
Rational Development of Combination Microbicide Therapies$174,780
R21 · FY2007 · AI · contact PI
Rational Development of Combination Microbicide Therapies$243,450
R21 · FY2006 · HD · contact PI
Development of Pyrimidinedione HIV Inhibitors as Topical Microbicides$99,826
R43 · FY2005 · AI
VIROLOGICAL EVALUATIONS OF STRATEGIES TO COMBAT HIV/AIDS$599,971
N01 · FY2000 · AI